Back
Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

339,504 studies
in
214 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 05/30/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 05/30/2020.
Displaying: 20 trials in your specialties ()
View trials across your selected specialties

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Primary Myelofibrosis, Anemia
View Full Trial
INTERVENTION

Drug: Luspatercept

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Mayo Clinic - Arizona, Phoenix, Arizona, United States

Brief Summary

This is a Phase 2, multicenter, open-label study to evaluate the efficacy and safety of luspatercept in subjects with MPN-associated myelofibrosis and anemia with and without RBC-transfusion dependence. The study is divided into a Screening Period, a Treatment Period (consisting of a Primary Phase, a Day 169 Disease Response Assessment, and an Extension Phase), followed by a Posttreatment Follow-up Period.

Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Myeloproliferative Neoplasm
View Full Trial
INTERVENTION

Drug: Vactosertib

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Weill Medical College of Cornell University, New York, New York, United States

Brief Summary

This study assesses the potential of using a TGFβ receptor inhibitor for the treatment of anemic patients with myeloproliferetive neoplasms. TGFβ signaling is known to be abnormally high in patients with myeloproliferative neoplasms and it is thought that abnormal TGFβ signals cause many of the problems with blood cell formation in these diseases. The study design allows all patients to receive the study drug, vactosertib. The dose of vactosertib is individualized within a pre-set range based upon its effectiveness and tolerability. A total of up to 37 patients will be treated.

ACE-536 Extension Study - Myelodysplastic Syndromes

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Myelodysplastic Syndromes
View Full Trial
INTERVENTION

Drug: ACE-536

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Acceleron Investigative Site, Dresden, Germany

Brief Summary

Study A536-05 is an open-label extension study for patients previously enrolled in study A536-03 (ClinicalTrials.gov Identifier NCT01749514), to evaluate the long-term safety and tolerability of ACE-536 in patients with low or intermediate-1 risk MDS.

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Pulmonary Arterial Hypertension
View Full Trial
INTERVENTION

Drug: Placebo, Drug: Sotatercept

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Pulmonary Associates, PA, Phoenix, Arizona, United States

Brief Summary

Study A011-09 is designed to assesses the efficacy and safety of sotatercept (ACE-011) relative to placebo in adults with pulmonary arterial hypertension (PAH). Eligible participants will receive study treatment for 6 months in the Placebo-Controlled Treatment Period, and then will be eligible to enroll into an 18- month Extension Period during which all participants will receive sotatercept. All treated patients will be also undergo follow-up period after last study drug treatment.

Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS TMPRSS6-LRx

  • Status
    Not yet recruiting
  • Phase
    Phase 2
  • Condition
    Beta Thalassemia Intermedia
View Full Trial
INTERVENTION

Drug: IONIS TMPRSS6-LRx

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Brief Summary

The purpose is to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of IONIS TMPRSS6-LRx administered subcutaneously to participants with non-transfusion dependent β-Thalassemia Intermedia.

ACE-536 Extension Study - Beta Thalassemia

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Beta-Thalassemia
View Full Trial
INTERVENTION

Drug: ACE-536

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Acceleron Investigative Site, Athens, Greece

Brief Summary

Study A536-06 is an open-label extension study for patients previously enrolled in study A536-04 (ClinicalTrials.gov Identifier NCT01749540), to evaluate the long-term safety and tolerability of ACE-536 in adult patients with beta-thalassemia.

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Pulmonary Arterial Hypertension
View Full Trial
INTERVENTION

Biological: Sotatercept

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

The University of Arizona, Tucson, Arizona, United States

Brief Summary

This study evaluates the effect of sotatercept (ACE-011) in adults with Pulmonary Arterial Hypertension. Each eligible participant will receive standard of care (SOC) plus sotatercept (ACE-011) for a 24 week treatment period followed by a 16 week follow up period.

MPN-RC 118 AVID200 in Myelofibrosis

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Post PV MF, Primary Myelofibrosis, Post-essential Thrombocythemia...
View Full Trial
INTERVENTION

Drug: AVID200

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Icahn School of Medicine at Mount Sinai, New York, New York, United States

Brief Summary

Increased levels of TGF-β1 were detected in serum, plasma and BM and positively correlated with both grade of BMF and extent of leukemic cell infiltration in the marrow. TGF-β likely plays a dual role in promoting myelofibrosis and myeloproliferation, both of which are the bone marrow morphologic hallmark of MF. AVID200 is a drug that targets TGF-β1 and TGF-β3. The study team hypothesizes that inhibiting the TGF-β signaling pathway in MF will decrease the fibrogenic stimuli leading to myelofibrosis and concomitantly interrupt myeloproliferation and restore normal hematopoiesis. This is a first in human, open-label, multicenter, Phase I/Ib trial of AVID200. Patients must have intermediate-2 or higher primary myelofibrosis (PMF), post-essential thrombocythemia or polycythemia-vera related MF (Post ET/PV MF). This study will enroll up to 24 patients. AVID200 is delivered by IV infusion on day 1 of each 3 week cycle.

Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Subjects Who Require Regular RBC Transfusions Due to Beta (β)-Thalassemia.

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Beta-Thalassemia
View Full Trial
INTERVENTION

Drug: ACE-536, Drug: ACE-536

Eligibility
  • Ages: 6 to 18 Months (Child)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Children's Hospital of Los Angeles, Los Angeles, California, United States

Brief Summary

This is a Phase 2a study to evaluate the safety and pharmacokinetics (PK) of luspatercept in pediatric subjects who require regular RBC transfusions due to β-thalassemia. At least 12 subjects are planned to be enrolled per each of the 4 age-group strata at 2 different dose levels. Any subject benefiting from the study treatment (at the Investigator's discretion), at the completion of the Treatment Period, will be offered the opportunity to continue luspatercept and long-term follow-up in the Long-term Treatment and Follow-up Period. Subjects entering the Long-term Treatment and Follow-up Period will continue to receive luspatercept at the same dose level as during the Treatment Period for up to 5 years from their first dose (Cycle 1 Day 1) or when the drug is approved for pediatric patients (whichever comes first). Subjects who receive treatment for the full 5 years will then have an End of Treatment visit and then a Post End of Treatment visit (12 weeks from last dose). Any subject that discontinues treatment prior to 5 years from Cycle 1 Day 1 will be have an End of Treatment visit, a Post End of Treatment visit (12 weeks from last dose), and then will continue in Long-Term Posttreatment Follow-up until 5 years from Cycle 1 Day 1 or until they withdraw consent/assent, are lost to follow-up, or the End of Trial, whichever occurs first.

A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Myelodysplastic Syndromes
View Full Trial
INTERVENTION

Drug: Luspatercept, Other: Placebo

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Stanford Cancer Center, Stanford, California, United States

Brief Summary

The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in subjects with anemia due to IPSS-R very low, low, or intermediate MDS with ring sideroblasts who require RBC transfusions.